SavedAdd your journal

Journals / Maltepe Tıp Dergisi / 2020 / Cilt: 12 - Sayı: 2

Evaluation of Treatment of Patients with SARS-CoV-2 in line with Literature

SARS-CoV-2 Tanısı ile Takip Edilen Olguların Tedavisinin Literatür Eşliğinde Sistematik Olarak Değerlendirilmesi

Numan KARAARSLAN
Mustafa DOGAN
Ibrahim YİLMAZ
Bulent BILIR
Fatma HACIOGLU
Lutfi ONAR
Hanefi ÖZBEK
Pages
49–58
Publication Date
2020-08-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Not only rRT-qPCR test results and CT findings but also clinical evidence should be considered for the diagnosis of SARS-CoV-2.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The present article aimed to evaluate the drug therapy applied to patients who were followed up for SARS-CoV-2, and who were tested positive and negative 2019-nCov.
📊
Key Findings & Data:Materials and Methods: A comprehensive and systematic literature search of numerous electronic databases regarding patients SARS-CoV-2 was performed.
💡
Conclusion & Impact:Conclusion: Not only rRT-qPCR test results and CT findings but also clinical evidence should be considered for the diagnosis of SARS-CoV-2.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:COVID-19 · hidroksiklorokin · lopinavir/ ritonavir

Abstract

Aim: The present article aimed to evaluate the drug therapy applied to patients who were followed up for SARS-CoV-2, and who were tested positive and negative 2019-nCov. Materials and Methods: A comprehensive and systematic literature search of numerous electronic databases regarding patients SARS-CoV-2 was performed. Results: Patients with 2019-nCoV can be treated with ceftriaxone, moxifloxacin, oseltamivir, hydroxychloroquine, and patients with poor prognosis can also be given lopinavir/ritonavir. Conclusion: Not only rRT-qPCR test results and CT findings but also clinical evidence should be considered for the diagnosis of SARS-CoV-2.

Özet

Amaç: SARS-CoV-2 tanısı ile takip Edilen, 2019-nCov testi için pozitif ve negatif sonuçlar alınan olgulara uygulanan ilaç tedavisinin literatür eşliğinde değerlendirilmesi amaçlandı. Materyal ve Metotlar: Elektronik ortamda; 2019-nCoV nedeni ile SARS-CoV-2 tanısı ile takip edilen olgulara ait verilerin, ülke ve dil kısıtlaması olmaksızın literatürde yerini alan araştırma sonuçları ile kıyaslanması gerçekleştirildi. Bulgular: Seftriakson, moksifloksasin, oseltamivir, hidroksiklorokin ve prognozu kötüye giden olgularda, gerektiğinde lopinavir/ritonavir etken maddeli farmasötikler ile 2019-nCoV’un tedavi edilebileceği gözlemlendi. Sonuç: SARS-CoV-2 tanısı için sadece rRT-qPCR testi ya da radyolojik olarak CT bulguları ile karar verilmemelidir. Her iki analiz sonuçlarına ek olarak klinik bulgular ile ortak paydada karar verilerek, tanı sonrası uygun tedavi modaliteleri düzenlenmelidir.

🔖

Cite This Article

KARAARSLAN, N., DOGAN, M., YİLMAZ, I., BILIR, B., HACIOGLU, F., ONAR, L., ÖZBEK, H. (2020). Evaluation of Treatment of Patients with SARS-CoV-2 in line with Literature. Maltepe Tıp Dergisi, Cilt: 12 - Sayı: 2, 49–58. https://ajindex.com/articles/230957

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. ICD-10-CM Official Coding Guidelines - Supplement Coding encounters related to COVID-19 Coronavirus Outbreak Effective: February 20, 2020, Accessed on 28.03.2020.
  2. COVID-19 National Emergency Response Center, Epidemiology and Case Management Team, Korea Centers for Disease Control and Prevention. Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea. Osong Public Health Res Perspect. 2020;11(1): 8-14
  3. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Accessed on 27.03.2020.
  4. WHO Director-General's opening remarks at the media briefing on COVID-19- 11 March 2020. Accessed on 28.03.2020.
  5. Coronavirus: Europe now epicentre of the pandemic, says WHO. Accessed on 28.03.2020.
  6. Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health 2020; 25(3): 278-80
  7. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med 2020; 382(10): 970-1
  8. Adhikari SP, Meng S, Wu YJ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty 2020; 9(1): 29
  9. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol Accessed on 27 March 2020. https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25728 10.
  10. Karaarslan N, Yilmaz I, Ozbek H, et al. Systematic Evaluation of Promising Clinical Trials-Gene Silencing for the Treatment of Glioblastoma. Turk Neurosurg 2019; 29(3): 328-34
  11. Topuk S, Akyuva Y, Karaaslan N, et al. Is it Possible to Treat Osteosarcoma Using Oligonucleotides Confined into Controlled Release Drug Delivery Systems? Curr Pharm Biotechnol 2017; 18(6): 516-22
  12. Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). https://w